CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03728361
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:47.324227+00:00
Published At: 2025-12-18T00:00:00+00:00
Record Updated At: 2025-12-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Grade I Neuroendocrine Carcinoma", "Grade II Neuroendocrine Carcinoma", "Grade III Neuroendocrine Carcinoma", "Metastatic Neuroendocrine Carcinoma", "Neuroendocrine Carcinoma", "Recurrent Small Cell Lung Carcinoma", "Refractory Small Cell Lung Carcinoma", "Lung Cancer Stage IV", "Large Cell Neuroendocrine Carcinoma", "Neuroendocrine Tumors", "Small Cell Lung Cancer Metastatic", "Small-cell Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-18"
protocolSection.identificationModule.nctId: "NCT03728361"
protocolSection.identificationModule.officialTitle: "A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.